Alemtuzumab: autoimmune complications
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Alemtuzumab: autoimmune complications. Hypothyroidism, Hyperthyroidism, Grave’s orbitopathy. Fully referenced neurology checklist.
Thyroid
- Hypothyroidism
- Hyperthyroidism
- Grave’s orbitopathy
Renal
Locked: subscribe to see this section.
Haematological
Locked: subscribe to see this section.
Dermatological
Locked: subscribe to see this section.
Other autoimmune side effects
Locked: subscribe to see this section.
Acronym: ITP
Locked: subscribe to see this section.
References
- Dargahi N, Katsara M, Tselios T, et al. Multiple sclerosis: immunopathology and treatment update. Brain Sci 2017; 7(7) pii: E78.
- Havrdova E, Arnold DL, Cohen JA, et al; CARE-MS I and CAMMS03409 Investigators. Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology 2017; 89:1107-1116.
- Roos JCP, Moran C, Chatterjee VK, Jones J, Coles A, Murthy R. Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series. Eye (Lond) 2019; 33:223-229.
- Phelps R, Winston JA, Wynn D, et al. Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Mult Scler 2019; doi: 10.1177/1352458519841829 (Epub ahead of print).
- Cuker A, Bass AD, Nadj C, et al. Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management. Mult Scler 2019; 20:1352458518816612 (Epub ahead of print).
- And 18 more. Subscribe to see the full list
